Skip to main content
SpringerLink
Log in

Locoregional Treatment of Brain Tumors

  • Chapter
  • First Online:
Clinical Applications of Nuclear Medicine Targeted Therapy

  • 976 Accesses

Abstract

Glioblastoma multiforme (GBM), primary brain tumor, is the most common and most malignant of the glia tumors. It is characterized by the worst prognosis with a median overall survival time of only 9–15 months. The infiltrating character of the tumor, its molecular heterogeneity, as well as the protective effects of the blood-brain barrier are the main causes for the insufficiency of established frontline treatments (surgery, radiotherapy, and chemotherapy).

The best treatment strategy for patients with recurrent GBM is unclear and controversial. Even with established state-of-the-art treatment in almost 90% of patients, the recurrence of disease is observed and median survival after recurrence is less than 6 months.

An alternative method of treatment is to apply the drug locally. It has been shown that GBM overexpresses the of NK-1 receptor and substance P (SP) can be used as a ligand. Alpha emitters, with shorter range and higher energy than beta emitters, offer the new potential for selective irradiation of tumors, with minimizing damage to adjacent tissue.

This chapter describes the use of radiolabeled SP for intratumoral treatment of the glia tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;10:987–96.

    Article  Google Scholar 

  3. Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, North American Brain Tumor Consortium, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro-Oncology. 2008;10:162–70.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Tatter SB. Recurrent malignant glioma in adults. Curr Treat Options in Oncol. 2002;3:509–24.

    Article  Google Scholar 

  5. Chang SM, Theodosopoulos P, Lamborn K, Malec M, Rabbitt J, Page M, Prados MD. Temozolomide in the treatment of recurrent malignant glioma. Cancer. 2004;100:605–11.

    Article  CAS  PubMed  Google Scholar 

  6. Barbagallo GM, Jenkinson MD, Brodbelt AR. ‘Recurrent’ glioblastoma multiforme, when should we reoperate? Br J Neurosurg. 2008;22:452–5.

    Article  PubMed  Google Scholar 

  7. Park JK, Hodges T, Arko L, Shen M, Dello Iacono D, McNabb A, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol. 2010;28:3838–43.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Riva P, Arista A, Franceschi G, Frattarelli M, Sturiale C, Riva N, et al. Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: comparison of the results obtained in recurrent and newly diagnosed tumors. Cancer Res. 1995;55:5952s–6s.

    CAS  PubMed  Google Scholar 

  9. Merlo A, Hausmann O, Wasner M, Steiner P, Otte A, Jermann E. Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas. Clin Cancer Res. 1999;5:1025–33.

    CAS  PubMed  Google Scholar 

  10. Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol. 1998;16:2202–12.

    Article  CAS  PubMed  Google Scholar 

  11. Zalutsky MR. Targeted radiotherapy of brain tumours. Br J Cancer. 2004;90:1469–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Schumacher T, Hofer S, Eichhorn K, Wasner M, Zimmerer S, Freitag P, et al. Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study. Eur J Nucl Med Mol Imaging. 2002;29:486–93.

    Article  CAS  PubMed  Google Scholar 

  13. Kneifel S, Cordier D, Good S, Ionescu MC, Ghaffari A, Hofer S, et al. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p. Clin Cancer Res. 2006;12:3843–50.

    Article  CAS  PubMed  Google Scholar 

  14. Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, et al. MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010;51(2):311–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Barendsen GW. Modification of radiation damage by fractionation of dose anoxia + chemical protectors in relation to LET. Ann N Y Acad Sci. 1964;114(1):96–114.

    Article  CAS  PubMed  Google Scholar 

  16. Barendsen GW, Koot CJ, van Kerson GR, Bewley DK, Field SB, Parnell CJ. The effect of oxygen on the impairment of the proliferative capacity of human cells in culture by ionizing radiations of different LET. Int J Radiat Biol. 1966;10:317–27.

    CAS  Google Scholar 

  17. Wulbrand C, Seidl C, Gaertner FC, Bruchertseifer F, Morgenstern A, Essler M, Senekowitsch-Schmidtke R. Alpha-particle emitting (213)Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation. PLoS One. 2013;8(5):e64730.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Friesen C, Glatting G, Koop B, Schwarz K, Morgenstern A, Apostolidis C, et al. Breaking chemoresis- tance and radioresistance with [213Bi]anti-CD45 antibodies in leu- kemia cells. Cancer Res. 2007;67(5):1950–8.

    Article  CAS  PubMed  Google Scholar 

  19. Hennig IM, Laissue JA, Horisberger U, Reubi JC. Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer. 1995;61:786–92.

    Article  CAS  PubMed  Google Scholar 

  20. Cordier D, Forrer F, Bruchertseifer F, Morgenstern A, Apostolidis C, Good S, et al. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial. Eur J Nucl Med Mol Imaging. 2010;37:1335–44.

    Article  CAS  PubMed  Google Scholar 

  21. Cordier D, Forrer F, Kneifel S, Sailer M, Mariani L, et al. Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P: results from a phase I study. J Neuro-Oncol. 2010;100:129–36.

    Article  CAS  Google Scholar 

  22. Krolicki L, Morgenstern A, Kunikowska J, Koziara H, Królicki B, Jakuciński M, et al. Recurrent glioblastoma multiforme - local alpha emiters targeted therapy with 213Bi-DOTA-substance P. Eur J Nucl Med Mol Imaging. 2015;42:S84–5.

    Google Scholar 

  23. Krolicki L, Morgenstern A, Kunikowska J, Koziara H, Królicki B, Jakuciński M, et al. Secondary glioblastoma multiforme - local alpha emiters targeted therapy with Bi-213-DOTA-substance P. Eur J Nucl Med Mol Imaging. 2016;43:S158.

    Google Scholar 

Download references

Acknowledgments

The authors are indebted for use of parts of the 225Ac/213Bi to the US Department of Energy, Office of Nuclear Physics, Isotope Development and Production for Research and Applications Program.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Medical University of Warsaw, Warsaw, Poland

    Jolanta Kunikowska & Leszek Krolicki

  2. European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, Germany

    Alfred Morgenstern & Frank Bruchertseifer

Authors
  1. Jolanta Kunikowska
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alfred Morgenstern
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Frank Bruchertseifer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Leszek Krolicki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jolanta Kunikowska .

Editor information

Editors and Affiliations

  1. Department of Nuclear Medicine, Humanitas Gavazzeni Hospital, Bergamo, Italy

    Emilio Bombardieri

  2. Nuclear Medicine Therapy and Endocrinology, Istituto Nazionale dei Tumori, Milano, Italy

    Ettore Seregni

  3. Nuclear Medicine and Molecular Imaging Unit, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy

    Laura Evangelista

  4. Nuclear Medicine Division, Istituto Nazionale dei Tumori, Milano, Italy

    Carlo Chiesa

  5. Nuclear Medicine, Humanitas Research Hospital, Rozzano, Milano, Italy

    Arturo Chiti

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kunikowska, J., Morgenstern, A., Bruchertseifer, F., Krolicki, L. (2018). Locoregional Treatment of Brain Tumors. In: Bombardieri, E., Seregni, E., Evangelista, L., Chiesa, C., Chiti, A. (eds) Clinical Applications of Nuclear Medicine Targeted Therapy . Springer, Cham. https://doi.org/10.1007/978-3-319-63067-0_35

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-63067-0_35

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-63066-3

  • Online ISBN: 978-3-319-63067-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation